Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article reviews research on ashitaba and related compounds. It is informational only and is not medical advice. Not medical advice. Consult a qualified healthcare professional before adding any supplement to your routine, particularly if you take medications or have any ongoing health condition.

If you’ve been reading about the autophagy research that followed Yoshinori Ohsumi’s 2016 Nobel Prize and came across ashitaba — a large leafy herb with yellow-sapped stems grown on Japan’s Pacific-facing islands — the framing in most wellness coverage runs between “Japanese longevity superfood” and “the next autophagy supplement after spermidine.” Neither framing tells you much about what the research has actually measured or what taking it as a capsule might realistically do.

What follows is a closer reading of what the evidence involves, where the gaps are, and how ashitaba sits relative to other Japanese supplement options.

TL;DR

• Ashitaba (Angelica keiskei) contains chalcone polyphenols — primarily 4-hydroxyderricin and xanthoangelol — that have attracted laboratory research interest for their apparent effects on autophagy pathways.
• A 2017 study published in Nature Communications (Jansen et al.) found that chalcone-class compounds were associated with autophagy induction in yeast, C. elegans, and mammalian cell lines, and with lifespan extension in model organisms.
• The evidence is currently in vitro and animal models. No large-scale human RCTs have measured ashitaba supplementation against longevity or clinical outcomes.
• Traditional use is regional — primarily the Izu Peninsula and Hachijojima island in Japan — where ashitaba has been consumed as a vegetable rather than as an isolated supplement.
• Ashitaba and ashwagandha address different biological targets with different evidence bases. They are not competing products for the same goal.

What ashitaba is and where it grows

Angelica keiskei belongs to the Apiaceae family — the same plant family as angelica, parsley, and carrot — and is native to Japan’s warm Pacific coastal regions. The plant grows along the Izu Peninsula south of Tokyo, on Oshima and Niijima, and most densely on Hachijojima, an island roughly 300 kilometers south of Tokyo that has historically supplied most of the ashitaba consumed in Japan.

The name 明日葉 — “tomorrow’s leaf” — comes from the plant’s growth rate: cut the leaves today, and new ones push up by tomorrow. The stems, when cut, exude a yellow-orange sap that food producers and herbalists in Izu have long treated as the part of the plant with the most biologically interesting properties. That sap is chalcone-rich.

Traditional consumption in Izu and Hachijojima takes straightforward forms: young leaves tempura-fried, chopped into salads, added to miso soup, or dried and steeped as tea. For several generations of island residents, ashitaba was eaten as a seasonal vegetable, not taken in capsule form. That distinction matters when reviewing the safety data later.

The chalcone compounds and what the autophagy research found

Chalcones are a class of polyphenol compounds — structurally distinct from flavonoids but chemically related — found in various plants. In ashitaba, the principal chalcones documented in the botanical literature are 4-hydroxyderricin and xanthoangelol. The yellow color of the cut stems is largely attributable to these compounds, which accumulate in the roots and stems at higher concentrations than in the leaves.

These chalcones drew laboratory attention because of their apparent ability to modulate cellular pathways involved in stress response. A 2017 study published in Nature Communications by Jansen et al. examined the effect of chalcone-class compounds on autophagy — the cellular recycling process by which damaged proteins and organelles are sequestered in autophagosomes and broken down for reuse. This research sits within a larger body of work on naturally occurring small molecules that can activate autophagy pathways, which expanded considerably after Ohsumi’s Nobel recognition for characterizing the molecular machinery of the process.

The Jansen et al. findings, in brief: chalcone-class compounds were associated with autophagy induction in yeast, in C. elegans worm models, and in mammalian cell lines. In the simpler model organisms, lifespan extension correlated with the autophagy induction. The proposed mechanism involves suppression of mTOR-dependent signaling — the same nutrient-sensing pathway through which fasting conditions are thought to activate autophagy — and possibly activation of mitophagy, the selective autophagy of damaged mitochondria.

That mechanism is biologically coherent and connects ashitaba’s chalcones to a well-studied longevity research axis. What it does not establish: that consuming ashitaba powder or capsules at commercially available doses will induce clinically meaningful autophagy in humans, extend healthy lifespan, or produce measurable changes in aging-related biomarkers in a controlled trial.

The evidence gap between in vitro and animal results and confirmed human clinical outcomes is a recurring theme across this research category. NMN raises NAD+ in humans — the bioavailability mechanism translates — but whether higher NAD+ improves clinical healthspan endpoints remains an open question. Resveratrol showed direct SIRT1 activation in cell models, a finding that required substantial revision in later mechanistic work. Ashitaba’s chalcone research is at an earlier stage than either. “Preliminary in humans” is an accurate description. “Not established in humans” is equally accurate.

For a broader look at how the Ohsumi autophagy research connects to fasting and supplement interventions currently available, see Ohsumi’s Nobel and the fasting question.

Hachijojima and the food culture context

Hachijojima appears in Japanese media as an island with relatively healthy elderly residents, and ashitaba is frequently invoked in that framing. The connection is plausible as one dietary variable among many — the island’s traditional diet also includes abundant fish, sweet potato, and fermented vegetables — but no controlled epidemiological study isolates ashitaba’s specific contribution to any demographic outcome. This is a food-culture observation, not a controlled cohort.

What the Hachijojima context does provide is reasonable confidence that long-term consumption of ashitaba as food — in traditional serving sizes as a cooked vegetable — is well-tolerated in a population that has eaten it for generations. That is a different frame from supplement-dose intake of concentrated extract, and tolerability data from traditional food use does not automatically extend to higher-concentration supplement forms. Supplemental doses may concentrate specific compounds considerably beyond what regular vegetable consumption delivers.

Ashitaba vs. ashwagandha: different evidence for different goals

Ashwagandha — specifically the KSM-66 and Sensoril standardized extracts — has a substantially larger human RCT base than any Japanese adaptogen or plant-based supplement in the longevity category. Multiple placebo-controlled trials have measured effects on perceived stress, cortisol, sleep quality, and fatigue. Effect sizes are moderate and have been replicated by independent research groups. See Ashwagandha vs. Japanese adaptogens: what the RCT evidence shows for the full comparison.

Ashitaba is not competing for the same goals. Ashwagandha’s evidence is primarily in the HPA axis — cortisol and stress response. Ashitaba’s research interest is in the autophagy and mTOR axis — cellular recycling and metabolic stress response. These are related but distinct biological targets, and the evidence levels are different: ashwagandha’s cortisol effects have been replicated in humans; ashitaba’s autophagy effects have been observed in yeast and cell models.

Someone managing stress and sleep disruption who wants human trial support for whatever they take should look at KSM-66 ashwagandha before ashitaba. Someone specifically interested in Japanese plant-based autophagy research and willing to engage with earlier-stage evidence may find ashitaba worth watching as the clinical research develops — with realistic expectations about where the science currently sits.

Side effects and what to watch for

Ashitaba eaten as food has a long history in Japan without documented widespread adverse effects at dietary intake levels. At supplement doses, the safety picture is less formally characterized.

CYP3A4 interaction risk: Furanocoumarins — a compound class present in various Apiaceae plants — can inhibit CYP3A4, the liver enzyme responsible for metabolizing a broad range of medications. Whether the furanocoumarin content of ashitaba at supplement doses produces clinically relevant enzyme inhibition has not been characterized in peer-reviewed pharmacokinetic studies. Anyone taking medications with a narrow therapeutic window — certain anticoagulants, statins, calcium channel blockers, or immunosuppressants — should discuss ashitaba supplementation with their prescribing physician before starting.

Photosensitivity: Angelica species carry a known photosensitization association via furanocoumarins. Whether ashitaba supplement doses produce meaningful photosensitization in humans is not established in controlled data, but is worth flagging for anyone with significant sun exposure or photosensitivity.

Pregnancy and breastfeeding: No controlled human safety data exists for concentrated ashitaba supplementation in pregnancy or nursing. The same precaution that applies to most unstudied supplements applies here.

Culinary ashitaba preparations — a few leaves in miso soup or tempura — represent a fundamentally different compound exposure than a 1,000 mg daily capsule of concentrated extract. Tolerability data from food use does not transfer automatically.

Supplement options and how to buy

The ashitaba supplement market is smaller and less quality-standardized than categories like ashwagandha, NMN, or CoQ10. Available formats fall into three types:

Leaf powder: Dried and powdered ashitaba leaves, sold in bags for blending into water, smoothies, or tea. The green color, mild bitter taste, and vegetable-adjacent flavor profile distinguish it from processed extracts. This format is closest to traditional dietary use and likely delivers a more conservative compound concentration than standardized extracts.

Capsules: Ashitaba extract in capsule form, typically 500–1,000 mg per serving. Variability across brands is high — leaf vs. whole plant, extraction method, chalcone standardization all differ. A product that specifies chalcone content or standardization to 4-hydroxyderricin or xanthoangelol provides more interpretable information than one that only lists total plant weight.

Dried leaf tea: A format closest to traditional consumption, delivering compounds at a conservative concentration. For anyone wanting to explore ashitaba without a supplement dose commitment, this is the lowest-exposure entry point.

Ashitaba powder and capsule options from both Japanese and US brands are available on Amazon. For quality filtering: look for third-party testing documentation and, ideally, chalcone content specifications. Ashitaba leaf tea from Japan-based suppliers is available seasonally and represents the most conservative approach to trying the plant.

There is no established effective dose for ashitaba supplement extract in humans, because the human research needed to determine one does not yet exist. Common commercial serving sizes of 500 mg to 3,000 mg daily of dried leaf equivalent reflect market convention, not dose-response data from clinical trials.

Who should wait before starting

The honest framing for ashitaba in 2026: the mechanistic hypothesis connecting its chalcone compounds to autophagy is biologically interesting and grounded in real model-organism research. Human clinical evidence has not yet confirmed this. This places it in a category of supplements that reward watching as the science develops — not necessarily a reason to avoid it, but also not a basis for confident recommendation beyond the early-adopter context.

Individuals who should specifically consult a clinician first:

• Anyone taking medications metabolized by CYP3A4 (interaction risk from furanocoumarins)
• Anyone with chronic liver or kidney disease
• Pregnant or breastfeeding women
• Anyone already supplementing with other compounds targeting autophagy or mTOR pathways — stacking effects are not characterized

For those interested in the autophagy research angle without adding an unstudied variable: the strongest human evidence for autophagy-adjacent dietary interventions remains in caloric restriction and time-restricted feeding, reviewed in Ohsumi’s Nobel and the fasting question. Ashitaba represents a specific Japanese food-plant angle on the same biological axis — one that is likely to generate more human-context evidence in the coming years, particularly as the chalcone-autophagy research fields continue to intersect.

---

See also: Ashwagandha vs. Japanese adaptogens: what the RCT evidence shows, Taurine deficiency and aging: what the 2023 Science paper found.